BUY Granules India — ICICI Securities, 03 Nov 2026

BUYGranules India

Granules India share price target & all analyst calls

byICICI SecuritiesHorizon: NA (inferred 1 year)3 Nov 2026via Institutional / Brokerage Research

Entry₹797.6Inferred

Target₹975

Total upside +22.24%

Stop lossNot given

CMP₹799.651d ago

Active+0.26%+21.93%upside left 12 mo left

Follow ICICI Securities for new calls(64% target hit, 1085 closed calls)Get alerts Watch GRANULES for new buy/sell callsGet alerts See 7 other Long-term calls on GRANULES See 541 other Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 7 Nov, 5:25 pm IST

12 supporting8 neutral6 opposing

Supports the BUY call (12)

Long-term trend bullish — 200-day average rising over the past quarter

Technicals · trend·6 Nov · yesterday

4 other SEBI-registered advisors have active long-term BUY calls on this stock, with 1 issued in the last 14 days

Advisor consensus · same horizon·3 Nov · 4d ago

Granules India Q2 Results: Net profit jumps 39% on higher revenue, EBITDA margin improves

NewsCnbc-Tv18·2 Nov · 5d ago

Granules India reported Q2 FY27 revenue of INR 15,600 million, up 20% YoY, and PAT of INR 1,818 million, up 39% YoY. The company also reported a shift to a net cash position of INR 8,280 million.

BSE · Company Update·2 Nov · 5d ago

Granules India reported Q2 FY27 revenue of INR 15,600 million (up 20% YoY) and PAT of INR 1,818 million (up 39% YoY). The company also reported a shift to a net cash position of INR 8,280 million.

NSE · Press Release·2 Nov · 5d ago

Neutral / worth noting (8)

Granules India Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.

NSE · Outcome of Board Meeting·2 Nov · 5d ago

Granules India's Gagillapur facility received 11 observations from the USFDA following an inspection. The company stated none relate to data integrity or cross-contamination and there is no impact on

BSE · Company Update·30 Oct · 1w ago

Granules India Gagillapur FDA Inspection and Manufacturing Compliance Explained

NewsGoogle News·19 Oct · 3w ago

Weighs against the BUY call (6)

Here's why Granules India shares could see a reaction on Monday

NewsCnbc-Tv18·31 Oct · 1w ago

Granules India’s Gagillapur facility gets 11 observations in USFDA inspection

NewsCnbc-Tv18·30 Oct · 1w ago

Granules India's Gagillapur manufacturing facility received eleven observations from the USFDA following an inspection.

NSE · Press Release·30 Oct · 1w ago

Granules India Faces US FDA Inspection At Gagillapur Facility

NewsGoogle News·19 Oct · 3w ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Granules India

All analyst calls on Granules India

More from ICICI Securities

Every call and its outcome